Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-8143
Mugavero, M J; May, M; Harris, R; Saag, M S; Costagliola, D; Egger, M; Phillips, A; Günthard, H F; Dabis, F; Hogg, R; de Wolf, F; Fatkenheuer, G; Gill, M J; Justice, A; D'Arminio Monforte, A; Lampe, F; Miró, J M; Staszewski, S; Sterne, J A C (2008). Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice? AIDS, 22(18):2481-2492.
View at publisher
OBJECTIVE: To determine whether differences in short-term virologic failure among commonly used antiretroviral therapy (ART) regimens translate to differences in clinical events in antiretroviral-naïve patients initiating ART. DESIGN: Observational cohort study of patients initiating ART between January 2000 and December 2005. SETTING: The Antiretroviral Therapy Cohort Collaboration (ART-CC) is a collaboration of 15 HIV cohort studies from Canada, Europe, and the United States. STUDY PARTICIPANTS: A total of 13 546 antiretroviral-naïve HIV-positive patients initiating ART with efavirenz, nevirapine, lopinavir/ritonavir, nelfinavir, or abacavir as third drugs in combination with a zidovudine and lamivudine nucleoside reverse transcriptase inhibitor backbone. MAIN OUTCOME MEASURES: Short-term (24-week) virologic failure (>500 copies/ml) and clinical events within 2 years of ART initiation (incident AIDS-defining event, death, and a composite measure of these two outcomes). RESULTS: Compared with efavirenz as initial third drug, short-term virologic failure was more common with all other third drugs evaluated; nevirapine (adjusted odds ratio = 1.87, 95% confidence interval (CI) = 1.58-2.22), lopinavir/ritonavir (1.32, 95% CI = 1.12-1.57), nelfinavir (3.20, 95% CI = 2.74-3.74), and abacavir (2.13, 95% CI = 1.82-2.50). However, the rate of clinical events within 2 years of ART initiation appeared higher only with nevirapine (adjusted hazard ratio for composite outcome measure 1.27, 95% CI = 1.04-1.56) and abacavir (1.22, 95% CI = 1.00-1.48). CONCLUSION: Among antiretroviral-naïve patients initiating therapy, between-ART regimen, differences in short-term virologic failure do not necessarily translate to differences in clinical outcomes. Our results should be interpreted with caution because of the possibility of residual confounding by indication.
396 downloads since deposited on 22 Dec 2008
105 downloads since 12 months
|Contributors:||Antiretroviral Therapy Cohort Collaboration (ART-CC)|
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Clinic for Infectious Diseases
04 Faculty of Medicine > University Children's Hospital Zurich > Medical Clinic
|Dewey Decimal Classification:||610 Medicine & health|
|Deposited On:||22 Dec 2008 13:06|
|Last Modified:||05 Apr 2016 12:42|
|Publisher:||Lippincott Wiliams & Wilkins|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page